跳至主要内容
临床试验/2023-508769-33-00
2023-508769-33-00招募中4 期

Protocol with Progestin-primed Ovarian Stimulation (PPOS) in conventional treatment from the start of stimulation vs protocol with GnRH antagonists as a pituitary suppressor in patients who are going to undergo DUOSTIM with embryo accumulation for PGT-A of the embryos.

Ginefiv S.L.1 个研究点 分布在 1 个国家目标入组 144 人开始时间: 2024年3月11日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
144
试验地点
1
主要终点
number of euploid embryos

研究概览

简要总结

To study whether there is a difference in the number of euploid embryos obtained in two groups of patients who are going to accumulate embryos for PGT-A by means of double ovarian stimulation, comparing two methods of pituitary suppression: the use of gestagens from the beginning of stimulation and the use of GnRH antagonists.

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
性别
Female
接受健康志愿者

入选标准

  • Age less than 43 years .
  • Regular menstrual cycles between 21 and 35 days.
  • Indication for IVF with PGT-A
  • Both ovaries present.
  • Ability to participate and complete the study.
  • Give and sign consent to participate in the study.

排除标准

  • Endometriosis grade III/IV
  • Concurrent participation in another study

结局指标

主要结局

number of euploid embryos

number of euploid embryos

次要结局

未报告次要终点

研究者

发起方
Ginefiv S.L.
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Claudia Blancafort

Scientific

Ginefiv S.L.

研究点 (1)

Loading locations...

相似试验